Outcome of COVID-19 and Match-Population Analysis with Compassionate Use of Remdesivir
Abstract
Abstract: Objectives: To analyze treatment outcomes for patients with COVID-19 with and without compassionate use of Remdesivir.
Methods: A retrospective review of electronic medical records for patients who did not receive Remdesivir due to unavailability. Match-population analysis based on inclusion criteria for compassionate use Remdesivir of the patient population who received Remdesivir as reported in literature and patients without Remdesivir.
Results: Sixty-six percent of patients met the criteria for compassionate use Remdesivir, 41% required intensive care unit admission, 20% invasive ventilation, and 10% died. The median time of hospitalization for survivors was eight days.
In the separate group of patients who did not meet the criteria for compassion use Remdesivir, mortality among patients with CrCl > 30 ml min, an exclusion criterion, was significantly higher as compared with patients with CrCl < 30 ml min.
Conclusion: When compared with previously reported data from patients who received compassionate use Remdesivir, our population had notably fewer patients requiring invasive ventilation.
References
1. World Health Organization (WHO). Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) [Internet]. [cited 2020 Jun 12]. Available: https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf?fbclid=IwAR1k-CfPkkBnSshMxATg_HA6Bm5Y-nIoLKAXEl2SmTklooTJY42IcQ1oI00.
2. Johns Hopkins University of Medicine Coronavirus Resource Center. COVID-19 Map [Internet]. [cited 2020 Jul]. Available: https://coronavirus.jhu.edu/map.html?fbclid= IwAR0WthjsAIT3BkIApe7gjVazepLLf8rYMJohq7zEY2NgetQa2wEwss4DNlA.
3. Li G, Clercq ED. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev. 2020;19:149-50. Available: https://media.nature.com/original/magazine-assets/d41573-020-00016-0/d41573-020-00016-0.pdf.
4. Gilead Sciences. Gilead Sciences Statement on Access to Remdesivir Outside of Clinical Trials. 2020 Mar 22 [Internet]. [cited 2020 Jul]. Available: https://www.gilead.com/news-and-press/company-statements/gilead-sciences-statement-on-access-to-remdesivir-outside-of-clinical-trials.
5. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med 2020;382:2327-2336. DOI: 10.1056/NEJMoa2007016.
6. National Institute of Allergy and Infectious Diseases (NIAID). Adaptive COVID-19 Treatment Trial. NIH. US National Library of Medicine ClinicalTrials.gov [Internet]. [cited 2020 Jul]. Available: https://clinicaltrials.gov/ct2/show/NCT04280705.
7. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for treatment of Covid-19–preliminary report. N Engl J Med. 2020 May 22. DOI: 10.1056/NEJMoa2007764.
Copyright (c) 2020 Journal of Rare Diseases and Orphan Drugs
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
